IP Library Granted Patent US 12,397,030
Granted Patent B2
US 12,397,030 · App. 17/784,168 · Granted Aug 26, 2025

Polyphenol compositions and uses thereof

Inventors: Annalouise O'Connor (Gig Harbor, WA); Mark Houston (Nashville, TN)
Assignee: METAGENICS LLC
A61K36/185A61K31/01A61K31/05A61K31/352A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,030
App. No.
17/784,168
Granted
Aug 26, 2025
Kind
B2
Abstract

This disclosure provides a composition and a method for enhancing urolithin B production. As a result of this, due to known impact of urolithin B, this can enhance reverse cholesterol transport and HDL function and management of plasma lipid profile through enhanced production of urolithin B from pomegranate polyphenols by administering a composition comprising a synergistic mixture of pomegranate polyphenols, lycopene and quercetin. The improved HDL function and lipid profile of such composition may be attributed to the enhanced urolithin B production made possible by the combination. Increasing the levels of urolithin B through modulation of the intestinal microbiome metabolism of pomegranate polyphenols is a potential therapeutic target for managing these diseases.

Claims (13)

1. A composition comprising:

I) a synergistic combination consisting essentially of:

i) pomegranate extract with a total polyphenol content of 50% by weight or greater, and a punicalagin content of 30% by weight or greater;

ii) quercetin; and

iii) lycopene;

II) Vitamin E; and

III) at least one inactive ingredient selected from the group consisting of microcrystalline cellulose, silicon dioxide, magnesium stearate, and combinations thereof;

wherein the ratio of the total weight of the pomegranate polyphenols to total weight quercetin and lycopene in the composition is from about 1:0.1 to about 1:10;

wherein the composition is in the form of a serving, and wherein the pomegranate extract is present in the serving in an amount of from about 200 to about 600 mg, the quercetin is present in the serving in an amount of from about 500 to about 1500 mg, and the lycopene is present in the serving in an amount of from about 1 to about 50 mg; and

wherein the composition is encapsulated in hydroxypropyl methylcellulose or hypromellose and is in the form of at least one tablet, capsule, or caplet.

2. The composition of claim 1 , wherein the pomegranate extract is pomegranate polyphenols.

3. The composition of claim 1 , wherein the pomegranate extract is present in an amount of from about 15 wt. % to about 40 wt. %, the quercetin is present in an amount of from about 35 wt. % to about 85 wt. %, and the lycopene is present in an amount of from about 0.1 wt. % to about 5 wt. %, each based on 100 parts by weight of the pomegranate extract, quercetin, and lycopene.

4. The composition of claim 1 , comprising 28.2% by weight pomegranate polyphenols and 71.8% by weight of the combination of quercetin and lycopene.

Assignments (3)
SECURITY INTEREST Recorded Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
CHANGE OF NAME Recorded Feb 16, 2024
From: METAGENICS, INC.
To: METAGENICS LLC
Reel/Frame 066624/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: O'CONNOR, ANNALOUISE; HOUSTON, MARK
To: METAGENICS, INC.
Reel/Frame 060961/0908 →